Myostatin inhibitors, with their efficacy and low side effect potential, are promising as treatments for cancer cachexia, cirrhosis, skeletal muscle atrophy such as sarcopenia in the elderly, and neuromuscular diseases such as progressive muscular dystrophy [76]. Here, MSTN is linked to Cirrhosis.